Vivimed Labs Limited (VIVIMEDLAB)
Market Closed
13 Aug, 10:00
XNSE MSE Primary XNSE ₹
4. 96
-0.06
-1.1952%
₹
- Market Cap
- P/E Ratio
1.6% Div Yield
74,059 Volume
- Eps
₹ 5.02
Previous Close Want to track VIVIMEDLAB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
VIVIMEDLAB closed today lower at ₹4.96, a decrease of -1.1952% from yesterday's close, completing a monthly decrease of -12.9825% or -₹0.74. Over the past 12 months, VIVIMEDLAB stock lost -70.4586%.
VIVIMEDLAB is not paying dividends to its shareholders.
The last earnings report, released on May 28, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Vivimed Labs Limited has completed 1 stock splits, with the recent split occurring on Apr 06, 2016.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on MSE (INR).
VIVIMEDLAB Chart
Vivimed Labs Limited (VIVIMEDLAB) FAQ
What is the stock price today?
The current price is ₹4.96.
On which exchange is it traded?
Vivimed Labs Limited is listed on XNSE.
What is its stock symbol?
The ticker symbol is VIVIMEDLAB.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 1.6%.
What is its market cap?
As of today, no market cap data is available.
Has Vivimed Labs Limited ever had a stock split?
Vivimed Labs Limited had 1 splits and the recent split was on Apr 06, 2016.
Vivimed Labs Limited Profile
| Specialty Retail Industry | Consumer Discretionary Sector | - CEO | XNSE Exchange | Y937A1144 CUSIP |
| India Country | 607 Employees | - Last Dividend | 6 Apr 2016 Last Split | - IPO Date |
Overview
Vivimed Labs Limited, established in 1988 and headquartered in Hyderabad, India, is a prominent player in the pharmaceutical and specialty chemicals market. The company, along with its subsidiaries, is engaged in the manufacturing and selling of active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations primarily in India. Vivimed Labs operates across two major segments: Speciality Chemicals Business and Pharma Business. It caters to a wide range of therapeutic segments and industries, including home, personal, and industrial care. In addition to serving the domestic market, Vivimed Labs also exports its products, showcasing its global outreach.
Products and Services
Vivimed Labs offers a diverse portfolio of products and services across various sectors:
- Active Pharmaceutical Ingredients (APIs) and Intermediates: The company supplies APIs and intermediates to generic and ethical pharmaceutical companies worldwide, making a significant contribution to global healthcare.
- Finished Dosage Formulations: Vivimed Labs develops and produces a wide range of finished dosage forms, including capsules, tablets, syrups, liquids, nasal sprays, and ointments targeting therapeutic areas such as ophthalmic, nutraceuticals, dermatology, and pain management.
- Contract Manufacturing: Offering contract manufacturing services, Vivimed Labs provides customized solutions for capsules and tablets, syrups and liquids, and nasal sprays and ointments, addressing the needs of its partners in the pharmaceutical industry.
- Branded Formulations: The company markets branded formulations in various therapeutic segments, catering to the nuanced needs of patients and healthcare providers.
- Specialty Chemicals: Vivimed Labs produces specialty chemicals, including active ingredients primarily used in hair dye and photochromic applications, leveraging its chemical expertise in the industrial and personal care segments.
- Favulous Tablets: In response to the COVID-19 pandemic, Vivimed Labs introduced Favulous tablets, aimed at treating mild to moderate cases of COVID-19, showcasing the company's adaptability to global health challenges.
Contact Information
Address: 6-3-866/1/G 1, GMR Towers
Phone: 91 40 6608 6608
Website: https://www.vivimedlabs.com
